Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Clement

Showing results (241-250 of 565) with videos related to

Pageof 57
Sort By:
Nature Chemical Biology|July 3, 2007
Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancerAnna Rodina, Maria Vilenchik, Kamalika Moulick, et al.
Cell Reports|December 7, 2023
Molecular determinants of the crosstalk between endosomal microautophagy and chaperone-mediated autophagyGregory J Krause, Philipp Kirchner, Barbara Stiller, et al.
JCI Insight|April 11, 2023
Cytokine storm-based mechanisms for extrapulmonary manifestations of SARS-CoV-2 infectionMaria Del Nogal Avila, Ranjan Das, Joubert Kharlyngdoh, et al.
Diabetes Care|April 8, 2014
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOWDevjit Tripathy, Stephen C Clement, Dawn C Schwenke, et al.
European Journal of Endocrinology|June 9, 2020
Clinical considerations for the treatment of secondary differentiated thyroid carcinoma in childhood cancer survivorsHanneke M van Santen, Erik K Alexander, Scott A Rivkees, et al.
Journal of Neuroendocrinology|July 13, 2023
Elevated IGF-1 concentrations in children with low grade glioma: A descriptive analysis in a retrospective national cohortJiska van Schaik, Ichelle M A A van Roessel, Iris D Bos, et al.
Diabetes|July 19, 2013
Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlatesRalph A Defronzo, Devjit Tripathy, Dawn C Schwenke, et al.
Diabetes Care|September 25, 2013
Prediction of diabetes based on baseline metabolic characteristics in individuals at high riskRalph A Defronzo, Devjit Tripathy, Dawn C Schwenke, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 7, 2009
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer modelsEloisi Caldas-Lopes, Leandro Cerchietti, James H Ahn, et al.
Diabetes, Obesity & Metabolism|April 5, 2013
Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trialG A Bray, S R Smith, M A Banerji, et al.
Pageof 57

Showing results (241-250 of 565) with videos related to

Sort By:
Pageof 57
Nature Chemical Biology|July 3, 2007
Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancerAnna Rodina, Maria Vilenchik, Kamalika Moulick, et al.
Cell Reports|December 7, 2023
Molecular determinants of the crosstalk between endosomal microautophagy and chaperone-mediated autophagyGregory J Krause, Philipp Kirchner, Barbara Stiller, et al.
JCI Insight|April 11, 2023
Cytokine storm-based mechanisms for extrapulmonary manifestations of SARS-CoV-2 infectionMaria Del Nogal Avila, Ranjan Das, Joubert Kharlyngdoh, et al.
Diabetes Care|April 8, 2014
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOWDevjit Tripathy, Stephen C Clement, Dawn C Schwenke, et al.
European Journal of Endocrinology|June 9, 2020
Clinical considerations for the treatment of secondary differentiated thyroid carcinoma in childhood cancer survivorsHanneke M van Santen, Erik K Alexander, Scott A Rivkees, et al.
Journal of Neuroendocrinology|July 13, 2023
Elevated IGF-1 concentrations in children with low grade glioma: A descriptive analysis in a retrospective national cohortJiska van Schaik, Ichelle M A A van Roessel, Iris D Bos, et al.
Diabetes|July 19, 2013
Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlatesRalph A Defronzo, Devjit Tripathy, Dawn C Schwenke, et al.
Diabetes Care|September 25, 2013
Prediction of diabetes based on baseline metabolic characteristics in individuals at high riskRalph A Defronzo, Devjit Tripathy, Dawn C Schwenke, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 7, 2009
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer modelsEloisi Caldas-Lopes, Leandro Cerchietti, James H Ahn, et al.
Diabetes, Obesity & Metabolism|April 5, 2013
Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trialG A Bray, S R Smith, M A Banerji, et al.
Pageof 57